Market Cap 8.06M
Revenue (ttm) 10,000.00
Net Income (ttm) -6.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -60,000.00%
Debt to Equity Ratio 0.00
Volume 32,036
Avg Vol 55,882
Day's Range N/A - N/A
Shares Out 3.70M
Stochastic %K 64%
Beta 1.87
Analysts Sell
Price Target $20.00

Company Profile

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized super...

Industry: Biotechnology
Sector: Healthcare
Phone: 480 399 2822
Address:
211 East Osborn Road, Phoenix, United States
H177
H177 May. 13 at 9:51 PM
0 · Reply
4Realz
4Realz May. 12 at 1:30 PM
$CELZ 🤣
0 · Reply
H177
H177 May. 11 at 1:54 PM
0 · Reply
Kjstock
Kjstock May. 10 at 3:48 AM
$CELZ I don’t have time to run through it but they dropped the latest 10Q https://www.sec.gov/Archives/edgar/data/1187953/000147793226002893/celz_10q.htm
1 · Reply
Bobby_J_Bomb
Bobby_J_Bomb May. 8 at 1:48 PM
$CELZ 4+ when they give spine update?
1 · Reply
H177
H177 May. 8 at 9:11 AM
$CELZ https://www.biodefenseinc.com/
0 · Reply
H177
H177 May. 7 at 8:14 PM
0 · Reply
Peterb3346
Peterb3346 May. 7 at 12:07 PM
$CELZ undervalued by a factor of at least 50x.
0 · Reply
H177
H177 May. 4 at 7:08 PM
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy May. 4 at 4:03 PM
$CELZ : Momentum Building as Breakthrough Data Fuels Renewed Interest 🧬 Creative Medical Technology Holdings is gaining attention after its April 28 breakthrough, reporting a 93% response rate in its Ultrasome knee osteoarthritis program. Strong clinical results combined with improving price action are starting to bring momentum back to the story. Technical View: 🔸 Tight consolidation with buyers stepping in on dips 🔸 Higher lows forming, showing strength 🔸 Price compressing beneath resistance Key Levels to Watch: 📈 $2.02 🟰 Key support 📈 $2.21–$2.51 🟰 Current consolidation range 📈 $2.74 🟰 Breakout level 📈 $3.08–$3.34 🟰 Major resistance zone 📈 $3.86 🟰 High timeframe resistance With strong clinical momentum and multiple catalysts ahead, CELZ is targeting $100B+ markets, positioning itself for increased attention as the story continues to unfold. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyCELZ1 Sector Peers: $CYCN $DYAI $MBRX $AIXC
1 · Reply
Latest News on CELZ
Creative Medical achieves second WHO INN milestone

2026-02-10T14:06:26.000Z - 3 months ago

Creative Medical achieves second WHO INN milestone


Creative Medical launches Biodefense Inc. Veterans Initiative

2025-10-30T13:20:14.000Z - 6 months ago

Creative Medical launches Biodefense Inc. Veterans Initiative


Creative Medical issues letter to shareholders

2025-10-27T12:30:51.000Z - 7 months ago

Creative Medical issues letter to shareholders


Creative Medical receives notice of allowance for ImmCelz

2025-07-11T12:10:13.000Z - 10 months ago

Creative Medical receives notice of allowance for ImmCelz


Creative Medical Technology Holdings Provides Corporate Update

Jul 10, 2024, 8:30 AM EDT - 2 years ago

Creative Medical Technology Holdings Provides Corporate Update


H177
H177 May. 13 at 9:51 PM
0 · Reply
4Realz
4Realz May. 12 at 1:30 PM
$CELZ 🤣
0 · Reply
H177
H177 May. 11 at 1:54 PM
0 · Reply
Kjstock
Kjstock May. 10 at 3:48 AM
$CELZ I don’t have time to run through it but they dropped the latest 10Q https://www.sec.gov/Archives/edgar/data/1187953/000147793226002893/celz_10q.htm
1 · Reply
Bobby_J_Bomb
Bobby_J_Bomb May. 8 at 1:48 PM
$CELZ 4+ when they give spine update?
1 · Reply
H177
H177 May. 8 at 9:11 AM
$CELZ https://www.biodefenseinc.com/
0 · Reply
H177
H177 May. 7 at 8:14 PM
0 · Reply
Peterb3346
Peterb3346 May. 7 at 12:07 PM
$CELZ undervalued by a factor of at least 50x.
0 · Reply
H177
H177 May. 4 at 7:08 PM
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy May. 4 at 4:03 PM
$CELZ : Momentum Building as Breakthrough Data Fuels Renewed Interest 🧬 Creative Medical Technology Holdings is gaining attention after its April 28 breakthrough, reporting a 93% response rate in its Ultrasome knee osteoarthritis program. Strong clinical results combined with improving price action are starting to bring momentum back to the story. Technical View: 🔸 Tight consolidation with buyers stepping in on dips 🔸 Higher lows forming, showing strength 🔸 Price compressing beneath resistance Key Levels to Watch: 📈 $2.02 🟰 Key support 📈 $2.21–$2.51 🟰 Current consolidation range 📈 $2.74 🟰 Breakout level 📈 $3.08–$3.34 🟰 Major resistance zone 📈 $3.86 🟰 High timeframe resistance With strong clinical momentum and multiple catalysts ahead, CELZ is targeting $100B+ markets, positioning itself for increased attention as the story continues to unfold. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyCELZ1 Sector Peers: $CYCN $DYAI $MBRX $AIXC
1 · Reply
jcooptechit
jcooptechit May. 4 at 4:03 PM
$CELZ SMART MONEY HEAT MAP IS FLASHING BULLISH CELZ is starting to look like a chart where the base has been built, the trend has shifted, and buyers are quietly stepping back in. The major level to watch is $2.50. A clean breakout above $2.50 could unlock momentum expansion and put $3.31 major resistance directly in play. Key Levels: 🔸Support/Accumulation: $1.70–$1.82 🔸 Reaccumulation: $2.15–$2.32 🔸 Breakout Trigger: $2.50 🔸 Major Resistance: $3.31 🔸 Target Zone: $3.68–$4.21 With the downtrend broken, higher lows forming, and CELZ building inside an ascending channel, the chart is showing signs that bulls may be gaining control. Communicated - Disclaimer: https://fh.bio/jcoop
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy May. 4 at 1:46 PM
$CELZ : A Microcap Biotech Targeting Massive Markets 🧬 Creative Medical Technology Holdings is a regenerative biotech developing stem cell therapies for chronic pain, diabetes, and immune conditions. 🔥 April 28 Breakthrough ✔️ Reported 93% response rate in Ultrasome knee OA study ✔️ Improved pain and mobility, no serious adverse events ✔️ Derived from CELZ-201, enabling a scalable cell free platform Recent Milestones ✔️ Completed enrollment in Phase 2 ADAPT trial ✔️ Positive interim data with strong response rates ✔️ Second WHO INN milestone, dual programs recognized Catalysts to Watch 🗓️ Full Phase 2 ADAPT data readout expected in 2026 🗓️ Expansion of Ultrasome into larger clinical studies 🗓️ Potential partnership or licensing discussions CELZ is expanding into a broader regenerative platform targeting osteoarthritis, chronic pain, and diabetes, a $100B+ opportunity. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyCELZ1 Sector Peers: $VXRT $HOOK $ATOS
0 · Reply
jcooptechit
jcooptechit May. 4 at 1:43 PM
🚨 93% RESPONSE RATE… AND $CELZ IS STILL UNDER THE RADAR 🧬 Ultrasome (derived from CELZ-201): ▪️ 93% response rate (pain + mobility) ▪️ ZERO serious adverse events ▪️ Cell-free, off-the-shelf = scalable 💡 This is the shift: Cell therapy ➝ mass-producible biologics 📊 THE SETUP ➝ Support: $1.20–$1.40 ➝ Resistance: $1.75–$1.90 ➝ Breakout: $2.00+ ➝ Targets: $2.50/ $3.00/ $4.00+ 📅 CATALYSTS ▪️ More clinical data ▪️ ADAPT trial updates ▪️ Partnerships / commercialization ⚠️ Multi-billion market + scalable model + strong data… CELZ feels like early-stage price discovery Watch this level closely 📣 Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers: $CAPR $AUTL $BMY
0 · Reply
BullTradeFinder
BullTradeFinder May. 4 at 1:37 PM
$CELZ Holding well, We need it to reclaim $2.30 for continued upside and get out of this chop range. Communicated-Disclaimer https://docs.google.com/document/d/1fwjSL77bbeirbtkV9xhygMAw1KQQyDa_h3Qw5uUSVeA/edit?usp=sharing
0 · Reply
H177
H177 May. 3 at 11:07 PM
0 · Reply
uppons
uppons May. 1 at 4:10 PM
0 · Reply
wokazn
wokazn May. 1 at 3:30 PM
$CELZ Ultrasome could be an IPSC, gene edited treatment, here is the patent application on it. https://www.patents-review.com/a/20250075185-orthopedic-regeneration-inducible-pluripotent-stem-cell.html
1 · Reply
wokazn
wokazn May. 1 at 3:08 PM
$CELZ 14 out of 15 gets you to 93% 🔥
0 · Reply
Peterb3346
Peterb3346 Apr. 30 at 2:07 PM
$CELZ your inability to do your own research/DD is astounding.
0 · Reply
hubal
hubal Apr. 30 at 12:26 PM
$CELZ how many patients were in the study? Where was it conducted? Could someone post details?
0 · Reply
BuyNHold4riches
BuyNHold4riches Apr. 30 at 11:05 AM
$CELZ no position but geez, if this is how this stock responds to good news, I wouldn’t want to see what happens with bad news.
0 · Reply
jcooptechit
jcooptechit Apr. 29 at 4:04 PM
$CELZ 93% RESPONSE RATE… AND THE MARKET IS STILL ASLEEP ON THIS? CELZ recently dropped a game-changing update that could redefine regenerative medicine. 🧬 Ultrasome (derived from CELZ-201) ▪️ 93% response rate in knee osteoarthritis (pain + mobility improvement) ▪️ ZERO serious adverse events ▪️ Built from GMP-grade CELZ-201: strong platform continuity ▪️ Cell-free, off-the-shelf therapy = scalable + lower cost 💡 What This Means: This isn’t just a trial update… this is validation of a scalable regenerative platform ▪️ From cell therapy: mass-producible biologics ▪️ From niche treatment: commercial opportunity ▪️ Partnerships + expanded clinicals now in focus ⚠️ Knee osteoarthritis is a multi-billion dollar market with limited long-term solutions. 🔥 93% response. Clean safety. Scalable model. How long before the market prices this in??? Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers: $MESO $FATE $CAPR
2 · Reply